GW405833 盐酸盐

更新时间：2025-08-25 11:49:39

GW405833 盐酸盐结构式	常用名	GW405833 盐酸盐	英文名	L-768242
	CAS号	180002-83-9	分子量	447.35
	密度	N/A	沸点	N/A
	分子式	C₂₃H₂₄Cl₂N₂O₃	熔点	47-49°C(lit.)
	MSDS	中文版美版	闪点	N/A
	符号	GHS06	信号词	Danger

GW405833 盐酸盐用途

GW-405833(L768242)是一种有效的选择性大麻素受体2(CB2)激动剂,EC50为50.7 nM。GW-405833还表现为非竞争性CB1拮抗剂。GW-405833抑制炎症和神经病理性疼痛[1][2]。

中文名	GW405833 盐酸盐
英文名	(2,3-dichlorophenyl)-[5-methoxy-2-methyl-3-(2-morpholin-4-ylethyl)indol-1-yl]methanone
中文别名	1-(2,3-二氯苯甲酰基)-5-甲氧基-2-甲基-3-[2-(4-吗啉基)乙基]-1H-吲哚
英文别名	更多

描述	GW-405833(L768242)是一种有效的选择性大麻素受体2(CB2)激动剂,EC50为50.7 nM。GW-405833还表现为非竞争性CB1拮抗剂。GW-405833抑制炎症和神经病理性疼痛[1][2]。
相关类别	研究领域 >> 炎症/免疫研究领域 >> 神经疾病信号通路 >> G 蛋白偶联受体/G 蛋白 >> 大麻素受体
靶点	CB2:50.7 nM (EC50) CB1:16.1 μM (EC50)
参考文献	[1]. Li AL, et al. Cannabinoid CB2 Agonist GW405833 Suppresses Inflammatory and Neuropathic Pain through a CB1 Mechanism that is Independent of CB2 Receptors in Mice. J Pharmacol Exp Ther. 2017 Aug;362(2):296-305. [2]. Li J, et al. Indole compounds with N-ethyl morpholine moieties as CB2 receptor agonists for anti-inflammatory management of pain: synthesis and biological evaluation. Medchemcomm. 2019 Sep 17;10(11):1935-1947.

熔点	47-49°C(lit.)
分子式	C₂₃H₂₄Cl₂N₂O₃
分子量	447.35
精确质量	446.11600
PSA	43.70000
LogP	4.76620
外观性状	固体
储存条件	2-8°C

符号	GHS06
信号词	Danger
危害声明	H301-H413
警示性声明	P301 + P310
个人防护装备	Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges
危害码 (欧洲)	T
风险声明 (欧洲)	25
安全声明 (欧洲)	45
危险品运输编码	UN 2811 6.1/PG 3
海关编码	2934999090

海关编码	2934999090
中文概述	2934999090. 其他杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%
申报要素	品名, 成分含量, 用途
Summary	2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Cannabinoids inhibit energetic metabolism and induce AMPK-dependent autophagy in pancreatic cancer cells.

Cell Death Dis. 4 , e664, (2013)

The anti-tumoral effects of cannabinoids have been described in different tumor systems, including pancreatic adenocarcinoma, but their mechanism of action remains unclear. We used cannabinoids specif...

Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism.

Cell Death Dis. 2 , e152, (2011)

Gemcitabine (GEM, 2',2'-difluorodeoxycytidine) is currently used in advanced pancreatic adenocarcinoma, with a response rate of < 20%. The purpose of our work was to improve GEM activity by addition o...

hms3268p12